FASTinov is an innovation-based company that develops next generation Antimicrobial resistance technologies. The company launched the world’s fastest susceptibility test, which delivers a result in less than 2 hours for bloodstream infections. These are life-threatening conditions often associated with sepsis, a condition that kills more than 10 million people annually. The emergence of bacterial species resistant to antimicrobials further increases the urgency of providing rapid diagnostics. FASTinov’s mission is to bring the fastest technologies to help in the fight against life-threatening infections. FASTinov SA was established in 2013 by clinicians from the University of Porto, Faculty of Medicine and is headquartered in Porto, Portugal.